2024-03-29T15:08:05Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02015563
2022-10-31T07:40:15Z
1642838163960:1642838198944:1642838199408:1642838224252
1642838403551:1642838412624
[総説]末梢動脈疾患に対する薬物+運動療法
Exercise and Pharmacological Intervention for Patient with Peripheral Arterial Disease
安, 隆則
Yasu, Takanori
exercise
intermittent
claudication
heparin
peripheral
arterial
disease
Trans Atlanticinter-Society Consensus (TASC)) II strongly recommends walking exercise and anti-platelet agents for patients with peripheral arterial disease(PAD).We have reported that a program combining heparin administration with exerciseis a useful therapeutic strategy for stimulation of collateral development in ischemic legs in patients with non-Option PAD via transient increase in hepatocyte growth factor. To examine a hypothesis that additional combination of lipo-Prestaglandin(PG)E1,a Potent vasodilator and inhibitor of platelet aggregation, accelerates the effectiveness of heparin + exercise program in patients with non-option PAD, 20 symptomatic no option PAD (Fontaine II or III)patients were randomly assigned in adouble blind fashion to two groups; a group of lipo-PGEl(+) (supervised walking for 60min/day after intravenous administration of 3,000 units heparin and 10 $ \mu $g lipo-PGE1 for 14days, n=10) and a group of lipo-PGEl(-) (same supervised walking program after administration of heparin and saline,n=10). After 14-day-initial treatment,the patients of both groups did ambulatory exercise under supervision for 60 min once a day, 3 days/week during a period of following 22 weeks. Additional administration of lipo-PGE1 on heparin + exercise program brings the therapeutic gain appearance forward.This beneficial short-term effect may encourage patients with non-Option PAD to maintain exercise trainlng.
論文
http://purl.org/coar/resource_type/c_6501
琉球医学会
Ryukyu Medical Association
2007
VoR
1346-888X
0289-1530
AN10369445
琉球医学会誌 = Ryukyu Medical Journal
3・4
26
98
95
jpn
open access
琉球医学会